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ABSTRACT
Estrogen plays important roles in breast cancer as it binds its receptor in breast tissue. 
The most studied variants in estrogen receptor a encoded by ESR1 gene are the ESR1 
PvuII and XbaI polymorphisms, which were associated with lower sensitivity to estrogen. 
We determined the proportion of ESR1 XbaI and PvuII polymorphisms in Javanese woman 
in Yogyakarta, Indonesia and analyzed the correlation between genetic variations with 
mammogram density. ESR1 XbaI and PvuII polymorphisms of 50 cases and 58 controls were 
identified using PCR-RFLP. Breast density was assessed based on digitizer mammograms. 
Quantitative analysis was performed using an interactive program based on cumulus 
of two thresholds. Mean of density and frequencies of SNPs were compared between 
cases and controls to identify the association between SNPs and cancer susceptibility. 
Mammographic density was significantly higher in cases (52%) than controls (0.41%) (p 
< 0.05). Women with one or two copies of the PvuII T allele and XbaI A allele had higher 
mammographic density compared with women with C and G alleles, respectively. The 
proportion between PP and TT genotype was not statistically significant (p > 0.05), while 
the proportion between AA and GG was significantly different (p < 0.05). Haplotype 2 
(CG/PX) was associated with lower sensitivity to estrogen and reflects a decrease of 
mammographic density. These findings were consistent with other studies that showed 
that ESR1 polymorphisms may affect breast cancer risk through differences in breast 
density. 
ABSTRAK
Estrogen memainkan peran penting dalam kanker payudara karena mengikat reseptor di 
jaringan payudara. Varian yang paling banyak dipelajari di reseptor estrogen a yang dikode 
oleh gen ESR1 adalah polimorfisme ESR1 PvuII dan XbaI, yang terkait dengan sensitivitas 
yang lebih rendah untuk estrogen. Kami menentukan proporsi polimorfisme ESR1 XbaI 
dan PvuII pada wanita Jawa di Yogyakarta, Indonesia dan menganalisis korelasi antara 
variasi genetik dengan kepadatan mammogram. Polimorfisme ESR1 XbaI dan PvuII dari 50 
kasus dan 58 kontrol diidentifikasi menggunakan PCR-RFLP. Kepadatan payudara dinilai 
berdasarkan digitizer mammogram. Analisis kuantitatif dilakukan dengan menggunakan 
program interaktif berbasis cumulus dari dua ambang batas. Rata-rata kepadatan dan 
frekuensi SNP dibandingkan antara kasus dan kontrol untuk mengidentifikasi hubungan 
antara SNP dan kerentanan terhadap kanker. Kepadatan mammografi secara signifikan 
lebih tinggi pada kasus (52%) dibandingkan kontrol (0,41%) (p <0,05). Wanita dengan 
satu atau dua salinan alel PvuII T dan XbaI A memiliki kepadatan mammografi lebih tinggi 
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dibandingkan dengan wanita dengan alel C dan G, secara berurutan. Proporsi antara 
genotipe PP dan TT tidak signifikan secara statistik (p> 0,05), sedangkan proporsi 
antara AA dan GG berbeda secara signifikan (p <0,05). Haplotype 2 (CG / PX) berkaitan 
dengan sensitivitas yang lebih rendah terhadap estrogen dan mencerminkan penurunan 
kepadatan mamografi. Temuan ini konsisten dengan penelitian lain yang menunjukkan 
bahwa polimorfisme ESR1 dapat mempengaruhi risiko kanker payudara melalui perbedaan 
kepadatan payudara.
Keywords: breast cancer - DNA polymorphism - ESR1 PvuII - ESR1 XbaI - mammogram 
Digitizer
INTRODUCTION
Breast cancer (BC) is the highest ranked 
malignancy in women in the world and is 
particularly frequent in Yogyakarta, Java, 
Indonesia.1,2 Estrogen plays an important 
role in the occurrence of BC through 
inducing proliferation and genotoxic effects 
by mechanisms involving estrogen binding 
to its receptor in breast tissue. However, the 
detailed mechanism of the induction of BC 
carcinogenesis is not fully understood.3 There 
are two types of estrogen receptor, estrogen 
receptor alpha, which is the main estrogen 
receptor that is encoded by the ESR1 gene, 
and estrogen receptor beta which is encoded 
by ESR2 gene.4 ESR1 is one of the most 
important mediators of hormonal response in 
estrogen-sensitive tissues such as the breast 
and plays a crucial role in breast growth and 
differentiation as well as in the development 
of cancer.5
Mammography density reflects the 
number of stromal and epithelial cells and 
is one of the strongest risk factors for BC. 
Some studies showed that women with a high 
density mammography pattern have a risk of 
BC 4–6 times higher than those with a low 
density pattern.6 An annual mammography 
examination is currently recommended for 
women over the age of 40 years,1 but not for 
women younger than 40 years, due to pain 
from compression techniques during the 
examination and the risk of radiation hazard.7 
Many studies have demonstrated evidence for 
the influence of estrogen on mammographic 
density.8-10 Women with hormone replacement 
therapy showed increased breast density.8,9 
Conversely, tamoxifen, a selective ER 
modulator and anti-estrogen, has been 
shown to decrease breast density and cancer 
risk.10 This suggests that the association of 
mammographic density with BC risk may 
occur through an estrogenic mechanism.
Research on the relationship between 
ESR1 polymorphism and mammographic 
density revealed different frequencies of 
ESR1 polymorphisms in different ethnics.11,12 
The most studied variants in the ESR1 gene 
are the PvuII and XbaI polymorphisms, which 
have been associated with lower sensitivity 
to estrogen.13 Determining the proportions of 
ESR1 XbaI and PvuII polymorphisms in BC 
cases in Yogyakarta may provide information 
that can be used as a preventive measure, 
especially for younger women who cannot 
be examined with mammography and as a 
reference for some interventions to reduce BC 
risk. 
MATERIALS AND METHODS 
Subjects
This study included BC patients admitted 
to Dr. Sardjito Genera Hospital, Yogyakarta 
in 2009–2010 who underwent pre-surgery 
mammography examinations, had been 
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diagnosed with BC and undergone mastectomy. 
The controls included women with no benign 
lesion based on breast examination, either 
using ultrasonography or mammography. All 
subjects agreed to participate in the study 
and provided signed informed consent. One 
hundred and eight blood samples from cases 
(n=50) and controls (n=58) were transported 
to the Molecular Biology Laboratory Faculty 
of Medicine Universitas Gadjah Mada for 
DNA extraction. Clinical data were obtained 
from medical records and directly filling out 
the questionnaire. 
Density analysis
Density analysis was carried out after the 
first mammogram scanning steps. The shape 
of a negative mammogram film is converted 
into digital form using a mammogram 
digitizer. Density analysis was performed 
using a special program. Quantitative analysis 
was performed using base system computer-
assisted methods of measurement with an 
interactive program based on two thresholds. 
The first threshold distinguishes breast tissue 
from the background in the mammogram. The 
second threshold is used to distinguish tissue 
in the breast itself. 
Polymerase chain reaction-restriction 
fragment length polymorphism (PCR-
RFLP)
Genomic DNA was extracted with 
saturated NaCl method. PCR was conducted 
in a total reaction volume of 25 µL, consisting 
of 100 ng genomic DNA, 2.5 µL 10 X PCR 
buffer, 0.75 µL MgCl 50 mm, 0.2 µL 25-mm 
dNTPs, 0.1 µL Platinum Taq (Invitrogen) 
and 10 pmol of each primer 1 µL forward- 
and reverse-coupled with DHPLC. The PCR 
reaction conditions were as follows: 95°C 
5 min, followed by 35 cycles of 95°C 35 s, 
annealing temperatures of 15 s and 72°C for 
25 s, followed by a final extension at 72°C 
for 10 min. PCR products were digested with 
XbaI and PvuII restriction enzymes (New 
England Biolabs) and visualized on 2.5–3% 
agarose gels containing ethidium bromide.
The homozygous mutant in ESR1 XbaI 
AA shows two bands sized 936 and 436 bp, 
the heterozygous AG produces three bands 
(1327, 936 and 436 bp), and the homozygous 
wildtype GG shows a single band size of 1327 
bp.9 For ESR1 PvuII, the TT homozygous 
mutant shows two bands sized 982 and 390 
bp, the heterozygous CT produces three bands 
(1372, 982 and 390 bp), and the homozygous 
CC wildtype shows a single band of 1327 bp.14
Statistical analysis
Data were analyzed with student t-test 
statistical analyses. P-values less than 0.05 
were considered significant.
RESULTS 
This study included 108 BC research 
subjects in Dr. Sardjito General Hospital, 
Yogyakarta between 2009 and 2010. The 
average age of subjects was 50.6 years and 
average age of controls was 48.72 years. The 
youngest subject among them was 33 years 
old and the oldest was 68 years old. There 
was no significant difference of age between 
cases and controls (p > 0.05). The percent 
mammogram density of cases was 52% and 
controls was 41%%. Compare means with 
independent sample t-test between cases and 
controls was significantly different (p < 0.05). 
We next performed PCR-RFLP of all cases. 
The ESR1 PvuII TT homozygous mutant 
showes two bands of 982 and 390 bp, the 
heterozygous CT produces three bands of 
1372, 982 and 390 bp, and the homozygous 
CC wildtype showes one band of 1327 bp 
(FIGURE 1).14 Furthermore the frequency 
of ESR1 PvuII polymorphism is presented in 
TABLE 1. 
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Green arrow: C/C, yellow arrow: C/T, red arrow: T/T
FIGURE 1. ESR1 PvuII polymorphism
TABLE 1. Frequency of ESR1 PvuII polymorphism
Allele
Case Control
Frequency % Frequency %
TT 15 30 6 10.3
TC 28 56 33 56.9
CC 7 14 19 32.8
The homozygous mutant in the ESR1 
XbaI AA shows two bands sized 936 and 436 
bp, the heterozygous AG produces three bands 
(1327, 936 and 436 bp), and the homozygous 
wildtype GG shows a band size of 1327 bp 
(FIGURE 2).14 Furthermore the frequency 
of ESR1 XbaI polymorphism is presented in 
TABLE 2. 
Green arrow: G/G, yellow arrow: G/A, red arrow: A/A
FIGURE 2. Polymorphism ESR1 XbaI
J Med Sci, Volume 49, No. 2, 2017 April: 72-79
76
TABLE 2. Frequency of ESR1 XbaI polymorphism
Allele
Case Control
Frequency % Frequency %
GG 2 4 10 17.2
AG 20 40 25 43.1
AA 28 56 23 39.7
We also analyzed and compared the 
mammography density in all groups. The 
mean percentage density in women with one 
or two copies of the PvuII p allele (CT/Pp 
and TT/pp, 49% and 48%, respectively) was 
higher than in those with the CC/PP genotype 
(39%). However, this difference did not 
show statistical significance (TT vs. CC, p > 
0.05). Women with one or two copies of the 
XbaI x allele had a higher mean percentage 
density (AG/Xx and AA/xx, 49% and 47%, 
respectively) than those with the GG/XX 
genotype (32%), and we detected a significant 
difference between AA and GG genotypes 
(p < 0.05). The percentages of heterozygous 
(CT) and homozygous (TT) PvuII in BC 
cases were higher (86%) than those in control 
(66%). The percentages of heterozygous (AG) 
and homozygous (AA) XbaI were also higher 
in BC cases (96%) compared with controls 
(82%).
DISCUSSION
The average age of the subjects in this 
study was 50.6 years. Age less than 50 years 
as many as 25 (50%), equal to or more than 
50 years 25 subjects (50%). A study in the 
United Kingdom in 2007 reported that most 
GC patients are over 50 years of age (81%).15 
These data reflect the high number of young 
GC survivors in Indonesia, especially in Java, 
which is consistent with the pattern of GC in 
Asian females.16 In general, the frequency of 
cancer incidence will increase in line with age. 
This increased incidence can be explained by 
the accumulation of somatic mutations in the 
human body. Another factor that plays a role 
is the decline in immune competence that 
accompanies the aging process. Although very 
few cases of BC occur in women in their teens 
or early 20s, BC is the second most common 
cancer diagnosed in women under 35 years. 
Approximately 1,400 BC cases are diagnosed 
each year among women aged 35–39 years. 
BC incidence rates generally increase with 
age, with the largest rate of increase before 
menopause.1 The differences in rates between 
patients after BC in Indonesia and in developed 
countries is probably because of the lower life 
expectancy in Indonesia and may also be due 
to specific genetic factors. 
Mammogram density 
High breast density on mammography 
is one of the strongest risk factors for BC. 
Breast density seen on a mammogram reflects 
differences in the number of stromal and 
epithelial cells and fatty tissue in the breast. 
Stroma and epithelium are radiologically 
will provide the density, while fat provides a 
radioluscent.17 The average mammographic 
density of BC cases is 52% with an average 
age 50.6%, but in control group 41% with an 
average age 48.7 % (p < 0.05). A previous 
study reported an average mammographic 
density in normal pre-menopausal women 
with an average age of 44.75 years of 28.7% 
and 23.64% in post-menopausal with an 
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average age of 55.95 years.18 Another study 
reported an average density in BC patients 
with an average age of 57.4 years of 36.7%, 
while the control group showed 30.6% 
with an average age of 56.8 years.19 These 
data showed that our study subjects had a 
higher average mammogram density than 
previous studies. Martin and Boyd proposed 
a hypothesis that the biological occurrence of 
mammogram density is determined by cell 
proliferation (mitogenesis) and cell damage 
caused by mutagens (mutagenesis). Both 
mitogenesis and mutagenesis are affected by 
many factors, including age, reproductive 
status, endogenous hormones and growth 
factors.20 The high-density mammogram 
data in this study support the hypothesis that 
mammogram density is one of the risks for 
BC. 
DNA polymorphisms XbaI and PvuII in 
ESR1
Estrogen is a mitogen that affects physio-
logical processes including cell growth. 
Estrogen is found in breast tissue and affects 
the regulation of cell growth. High estrogen 
levels are also reportedly associated with 
an increased risk of BC. Estrogen mostly 
exerts its cellular action through binding its 
receptor. Between the two forms of estrogen 
receptor α and b, estrogen receptor α plays 
an important role in BC because of its high 
prevalence in breast tissue.21 The ESR1 
gene, also known as ESRα, is located on 
human chromosome 6q25. ESR1 is a core 
receptor that mediates the action of estrogen 
or other steroid hormones that regulate gene 
transcription, especially in estrogen-sensitive 
tissues such as breast, and plays a crucial 
role in the growth and differentiation of BC. 
Most research has focused on the ESR1 PvuII 
(C/T) and XbaI (G/A) polymorphisms in 
intron 1.21 Both variants have implications in 
affecting transcription and gene expression. 
Some studies also indicate an increased risk 
of BC with polymorphisms at allele A and T 
(homozygous mutant) of XbaI and PvuII.22
In this study, percentage of heterozygous 
(CT) and homozygous mutant (TT) of PvuII in 
breast cancer cases (86%) higher than controls 
(66%). The percentage of heterozygous (AG) 
and homozygous mutant (AA) of XbaI in breast 
cancer cases (96%) also higher than controls 
(82%). The average percentage density was 
higher in women with one or two copies of 
the PvuII p allele (CT/Pp and TT/pp, 49% and 
48%, respectively) than in those with the CC/
PP genotype (39%). However, this difference 
did not show statistical significance (TT vs. 
CC). Women with one or two copies of the 
XbaI x allele had higher mean percentage 
density (AG/Xx and AA/xx, 49% and 47%, 
respectively) than those with the GG/XX 
genotype (32%), and we detected a significant 
difference between AA and GG genotypes.
The results of our study are consistent 
with those published by van Duijnhoven.23 
Mammographic density was significantly 
higher in women with one or two copies of 
p (T) allele in ESR1 PvuII. Haplotype ESR1 
gene 1 (px/TA) was also associated with 
increased mammographic density while 
haplotype 2 (PX/CG) was associated with a 
decrease in density. On the whole subject is a 
breast cancer contained a high percentage and 
high mammographic density of heterozygous 
and homozygous mutant compared with 
homozygous wild type at ESR 1 XbaI and 
ESR1 PvuII. The difference between the two 
groups which show high estrogen that effect 
mammographic density that is strong risk 
of breast cancer. Crandal et al. showed that 
genetic variation in sex steroids or estrogen 
receptors are in production in breast showed 
different degrees of proliferation that affect 
radiological picture as a mammogram density 
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differences.22 The existence of sex steroid 
metabolic enzymes and ESRs in breast tissue 
caused an activation of local estrogen that 
could potentially lead to reactive metabolites 
in breast tissue and may have a role in the 
initiation and promotion of carcinogenesis.
CONCLUSION
Our study showed that haplotype 1 (px/
TA) of ESR1 gene is associated with high 
sensitivity to estrogen and reflects an increase 
of mammographic density. Haplotype 2 
(CG/PX) is associated with lower sensitivity 
to estrogen and reflects a decrease of 
mammographic density. Our findings support 
the view that ESR1 polymorphisms may affect 
BC risk through differences in breast density.
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